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Capsule	summary		
LRBA	deficiency,	a	life-threatening	immunodeficiency/autoimmunity	disorder,	was	treated	
by	HSCT	in	12	patients,	four	of	whom	died	from	transplant-related	causes.	Six	patients	were	
cured	without	further	need	of	immunosuppression,	and	two	are	in	partial	remission.	
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To	the	Editor	1	
	2	
LPS-responsive	beige-like	anchor	protein	(LRBA)-deficiency	is	a	severe	primary	3	
immunodeficiency	with	a	variable	clinical	phenotype,	including	features	overlapping	with	4	
common	variable	immunodeficiency,	autoimmune	lymphoproliferative	syndrome,	immune	5	
dysregulation	polyendocrinopathy	enteropathy	X-linked	(IPEX)	syndrome,	and	an	association	6	
with	lymphoma1-3.	Despite	accumulating	experience,	the	procedure	of	allogeneic	7	
hematopoietic	stem	cell	transplantation	(HSCT)	to	treat	primary	multi-organ	autoimmunity	8	
disorders	and	combined	immunodeficiencies	with	immune	dysregulation	such	as	LRBA	9	
deficiency	is	not	routine.	First,	the	indication	and	optimal	time	point	are	undetermined.	10	
Second,	the	outcome	of	HSCT	in	syndromes	with	predominant	autoimmunity	is	unclear,	11	
given	that	target	antigens	of	autoimmune	reactions	remain	unchanged,	and	autoimmunity	12	
as	well	as	inflammation	may	persist	due	to	disease-causing	factors	extrinsic	to	the	13	
hematopoietic	and	immune	system.	For	instance,	LRBA	is	a	ubiquitously-expressed	protein	14	
functioning	in	autophagy	and	intracellular	vesicle	trafficking,	facilitating	cell	surface	15	
translocation	of	CTLA44,	5.	Its	relevance	in	tissues	other	than	immune	cells	is	unknown.		16	
Augmentation	of	regulatory	T	cell	function	in	LRBA-deficient	individuals	manifesting	with	17	
chronic	enteropathy	by	regular	CTLA4-Ig	infusions	potentially	induces	remission4.	However,	18	
not	all	symptoms	respond	equally,	and	patients	remain	dependent	on	CTLA4	substitution.	19	
Furthermore,	the	additional	use	of	steroids,	sirolimus,	hydroxychloroquine,	and	other	20	
immunosuppressants	may	not	prevent	the	long-term	deterioration	of	patients	with	this	21	
potentially	fatal	disease.	Finally,	CTLA4-Ig	is	not	available	in	many	countries	due	to	limited	22	
resources.	Although	HSCT	has	proven	helpful	in	single	patients1,	6-9,	early	reports	of	HSCT	in	23	
cases	of	LRBA	deficiency	indicated	a	higher	transplant-related	mortality	(TRM)	than	in	other	24	
inborn	errors	(2	of	first	4	patients);	it	is	unclear	whether	disease	status	at	time	of	HSCT	or	25	
other	disease-	or	transplant-related	factors	were	involved.	To	better	understand	the	role	of	26	
HSCT	as	a	potentially	curative	treatment	for	LRBA	deficiency,	we	performed	an	international	27	
EBMT-,	and	ESID-wide	survey	in	2016	to	collect	information	about	the	HSCT	experience.		28	
Data	were	obtained	in	accordance	with	the	Declaration	of	Helsinki	and	an	Institutional	Board	29	
review	(IRB00002556,	29-142ex16/17)	by	retrospective	chart	review	by	the	local	physicians.	30	
From	a	cohort	of	72	patients	with	LRBA	deficiency,	12	underwent	HSCT	between	2005-2016	31	
(Table	1).	Indications	for	transplant	included	refractory	immune	cytopenias,	gastrointestinal	32	
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problems,	parenchymal	lung	disease,	failure	to	thrive,	severe	neurological	or	infectious	33	
complications,	or	plainly	“severe	course	of	the	disease”	(Table	1	and	Figure	1A).	Overall	34	
survival	of	transplanted	patients	was	67%	(8/12	patients);	all	deaths	were	due	to	TRM	(pre-35	
existing	infections,	graft	failure,	multi-organ	failure,	thrombotic	microangiopathy)	and	36	
occurred	within	three	months	of	HSCT	(Table	1,	Figure	1,	and	Supplementary	Figure	1).	37	
Eleven	donors	were	HLA-matched	unrelated	or	family	donors	(4	and	7,	respectively).	One	of	38	
the	deceased	patients	was	the	only	subject	of	the	cohort	with	a	mismatched	(haploidentical	39	
family)	donor.	Surviving	patients	showed	mostly	favorable	degrees	of	remission	(complete:	40	
4;	good	partial:	2	[some	mild	or	moderate	potentially	LRBA-related	symptoms,	not	requiring	41	
immunosuppressive	therapy];	partial:	2	[amelioration	of	disease	but	need	of	42	
immunosuppression	for	potentially	LRBA-related	symptoms])	with	a	median	follow-up	of	26	43	
months	(range	4-142;	Table	1	and	Figure	1).	HSCT	course	and	recurrence	or	persistence	of	44	
symptoms	were	apparently	not	dependent	on	the	donor's	LRBA	status	or	on	type/intensity	45	
of	conditioning.	All	survivors	in	complete	or	good	partial	remission	showed	full	donor	46	
chimerism	(>95%	donor	white	blood	cells,	WBC).	Two	patients	with	partial	remission	47	
(requiring	immunosuppressive	treatment)	showed	declining	donor	WBC	chimerism	<90%:	48	
patient	3	had	89%	donor	WBC	and	88%	donor	T	cells	on	day	+240,	further	declining	to	83	49	
and	84%,	respectively,	on	day	+720,	and	was	treated	with	sirolimus	and	romiplostim	for	50	
moderate	immune	thrombocytopenia	and	autoimmune	hemolytic	anemia	(AIHA)	that	51	
developed	on	days	+90	and	+270,	respectively.	Patient	9,	with	only	7%	WBC	and	23%	T	cell	52	
chimerism	on	day	+578,	was	successfully	treated	with	abatacept	after	attempts	with	steroids	53	
and	rituximab	for	AIHA	(see	details	in	Table	1).	Both	patients	are	clinically	stable	under	the	54	
current	treatment	and	did	not	develop	other	autoimmune	symptoms	they	previously	55	
showed	due	to	LRBA	deficiency	(Fig.	1A,	Table	1).	Thus,	best	results	of	HSCT	for	LRBA	56	
deficiency	were	associated	with	full	donor	chimerism.	Donor	source,	transplant	regimen,	57	
GvHD	incidence,	and	disease	response	are	listed	in	Table	1	and	Figure	1.	Strikingly,	LRBA-58	
related	symptoms	resolved	or	decreased	significantly	in	number	and	intensity	and	59	
performance	scores	increased	in	all	HSCT	survivors	(Figure	1A-C).	Consequently,	the	need	for	60	
immunosuppressive	treatment	declined	and	most	patients	were	off	immunoglobulin	61	
replacement	post-HSCT	(Figure	1D-E).	Unfortunately,	there	are	no	up-to-date	follow-up	and	62	
survival	data	of	untransplanted	patients	beyond	previous	publications	of	large	cohort	63	
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studies,	that	reported	at	least	six	deceased	of	58	untransplanted	but	many	newly	diagnosed	64	
patients	and	family	members1,	2,	5.	65	
Although	the	number	of	patients	surveyed	was	too	small	to	routinely	recommend	HSCT	for	66	
LRBA-deficiency	based	on	the	evidence	collected,	these	data	support	the	feasibility	and	67	
curative	potential	of	HSCT	and	allow	us	to	state	three	important	points.		68	
First,	remissions	without	further	need	for	immunosuppression	are	achievable	and	occurred	69	
in	6	of	the	8	surviving	patients.	No	relapse	occurred	in	patients	with	full	donor	chimerism.	70	
Importantly,	although	the	treatment-requiring	autoimmune	cytopenias	in	patients	3	and	9	71	
observed	after	HSCT	are	possibly	caused	by	LRBA	deficiency	due	to	waning	donor	chimerism,	72	
they	could	also	be	attributed	to	graft	failure,	post-HSCT	immune	dysregulation,	or	marrow	73	
dysfunction,	like	suspected	in	the	growth	factor	responsive	thrombocytopenia	and	74	
neutropenia	of	patient	11,	as	such	sequelae	may	similarly	occur	in	HSCT	recipients	with	75	
other	underlying	diseases.	With	a	median	follow-up	of	2	years,	six	of	eight	patients	did	not	76	
need	further	pharmacological	immunosuppression	or	immunoglobulin	replacement	therapy,	77	
indicating	curability.	Only	one	patient	in	this	cohort	received	abatacept	as	bridging	78	
treatment	to	HSCT.	It	is	unclear	whether	response	to	abatacept	would	have	changed	the	79	
HSCT	indication.	However,	despite	the	overall	satisfying	responses	to	abatacept	(reported	in	80	
10	patients	in	the	cohort	of	72	patients),	the	long-term	dependency	on	this	treatment	with	81	
its	associated	potential	risks	remains.	The	risk	of	LRBA-related	lymphoma	or	82	
immunosuppression-associated	malignancy	would	be	anticipated	to	be	substantially	83	
reduced	or	abolished	in	HSCT	survivors,	as	well	as	the	future	risk	of	infections,	as	compared	84	
to	patients	undergoing	continuous	treatment	with	CTLA4-Ig,	sirolimus	or	other	85	
immunosuppression.	Thus,	based	on	the	present	results,	we	would	proceed	to	HSCT	if	a	86	
suitable	donor	is	present.	The	optimal	time	point	remains	to	be	determined,	but	it	can	be	87	
expected	that	long-term	organ	damage	will	impact	negatively	on	HSCT	results.		88	
Second,	among	the	small	cohort	of	12	LRBA-deficient	patients	who	were	transplanted	from	89	
heterozygous	LRBA	mutation	carriers	(n=6),	LRBA	wild-type	or	unrelated	donors	(n=5),	no	90	
correlation	between	residual	or	recurring	LRBA-related	symptoms	and	donor	LRBA	status	91	
was	detected,	arguing	against	a	dosage	effect	of	LRBA2,	6.		92	
Lastly,	these	data	indicate	that	any	alluded	LRBA-dependent	effects	outside	the	93	
(transplanted)	hematopoietic/immune	tissues	play	no	or	only	an	inferior	role	with	regard	to	94	
outcome	and	remission.		95	
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Together,	accepting	the	limitation	that	the	retrospective	case	series	lacked	a	matched	96	
control	group,	our	findings	strongly	support	the	use	of	early	HSCT	in	patients	with	severe	97	
presentations	of	LRBA	deficiency.	98	
	99	
Supplemental	Data	are	available	in	the	Journal’s	Online	Repository	at	www.xxxyyyzzz.org.	100	
	101	
Acknowledgements.	The	authors	thank	the	EBMT	and	the	ESID	for	providing	platforms	for	102	
data	accrual	and	Sara	Crockett	for	scientific	editing.	SOS	thanks	E.	Haapaniemi,	Karolinska	103	
Institutet,	Huddinge,	Sweden,	for	help	with	the	genetic	analyses.	MGS	was	in	part	funded	by	104	
the	Styrian	Children’s	Cancer	Aid	(Steirische	Kinderkrebshilfe).	The	work	was	also	supported	105	
by	the	BMBF	(grant	01EO1303	to	SE	and	BG).		106	
	107	
Authors	108	
Markus	G	Seidel,	M.D.,	Medical	University	Graz,	Austria	109	
Katrin	Böhm,	C.m.,	Medical	University	Graz,	Austria	110	
Figen	Dogu,	M.D.,	Ankara	University	School	of	Medicine,	Turkey	111	
Austen	Worth,	M.D.,	Institute	of	Child	Health,	UCL,	United	Kingdom	112	
Adrian	Thrasher,	M.D.,	Institute	of	Child	Health,	UCL,	United	Kingdom	113	
Benoit	Florkin,	M.D.,	Immuno-Hémato-Rhumatologie	Pédiatrique,	CHR	Citadelle,	Belgium	114	
Aydan	İkincioğulları,	M.D.,	Ankara	University	School	of	Medicine,	Turkey	115	
Anke	Peters,	M.D.,	Medical	Center,	University	of	Freiburg,	Germany	116	
Shahrzad	Bakhtiar,	M.D.,	University	Hospital	Frankfurt,	Germany	117	
Marie	Meeths,	M.D.,	Karolinska	University	Hospital	Solna,	Stockholm,	Sweden	118	
Polina	Stepensky,	M.D.,	Hadassah	Hebrew	University	Medical	Center,	Jerusalem,	Israel	119	
Isabelle	Meyts,	M.D.,	University	Hospitals	Leuven,	KU	Leuven,	Belgium	120	
Svetlana	O	Sharapova,	M.D.,	Belarusian	Research	Center	for	Pediatric	Oncology,	Hematology	and	Immunology,	Minsk	121	
Region,	Belarus	122	
Laura	Gámez-Díaz,	PhD,	Center	for	Chronic	Immunodeficiency	(CCI),	University	of	Freiburg,	Germany	123	
Lennart	Hammarström,	M.D.,	Karolinska	Institutet	at	Karolinska	University	Hospital	Huddinge,	Stockholm,	Sweden	124	
Stephan	Ehl,	M.D.,	Center	for	Chronic	Immunodeficiency	(CCI)	and	Medical	Center,	University	of	Freiburg,	Germany	125	
Bodo	Grimbacher,	M.D.,	Center	for	Chronic	Immunodeficiency	(CCI),	University	of	Freiburg,	Germany	126	
Andrew	R	Gennery,	M.D.,	Institute	of	Cellular	Medicine,	Newcastle	University,	Newcastle	upon	Tyne,	United	Kingdom	127	
…on	behalf	of	the	Inborn	Errors	Working	Party	(IEWP)	of	the	European	Group	for	Blood	and	Marrow	Transplantation	(EBMT)	128	
	 	129	
	 7	
	130	
References	131	
	132	
1.	 Gámez-Díaz	L,	August	D,	Stepensky	P,	Revel-Vilk	S,	Seidel	MG,	Noriko	M,	et	al.	The	133	
extended	phenotype	of	LRBA	deficiency.	Frontiers	in	Immunology	2015.	134	
2.	 Alkhairy	OK,	Abolhassani	H,	Rezaei	N,	Fang	M,	Andersen	KK,	Chavoshzadeh	Z,	et	al.	135	
Spectrum	of	Phenotypes	Associated	with	Mutations	in	LRBA.	J	Clin	Immunol	2016;	36:33-45.	136	
3.	 Charbonnier	LM,	Janssen	E,	Chou	J,	Ohsumi	TK,	Keles	S,	Hsu	JT,	et	al.	Regulatory	T-cell	137	
deficiency	and	immune	dysregulation,	polyendocrinopathy,	enteropathy,	X-linked-like	138	
disorder	caused	by	loss-of-function	mutations	in	LRBA.	J	Allergy	Clin	Immunol	2015;	135:217-139	
27.	140	
4.	 Lo	B,	Zhang	K,	Lu	W,	Zheng	L,	Zhang	Q,	Kanellopoulou	C,	et	al.	AUTOIMMUNE	141	
DISEASE.	Patients	with	LRBA	deficiency	show	CTLA4	loss	and	immune	dysregulation	142	
responsive	to	abatacept	therapy.	Science	2015;	349:436-40.	143	
5.	 Lopez-Herrera	G,	Tampella	G,	Pan-Hammarstrom	Q,	Herholz	P,	Trujillo-Vargas	CM,	144	
Phadwal	K,	et	al.	Deleterious	mutations	in	LRBA	are	associated	with	a	syndrome	of	immune	145	
deficiency	and	autoimmunity.	Am	J	Hum	Genet	2012;	90:986-1001.	146	
6.	 Seidel	MG,	Hirschmugl	T,	Gamez-Diaz	L,	Schwinger	W,	Serwas	N,	Deutschmann	A,	et	147	
al.	Long-term	remission	after	allogeneic	hematopoietic	stem	cell	transplantation	in	LPS-148	
responsive	beige-like	anchor	(LRBA)	deficiency.	J	Allergy	Clin	Immunol	2015;	135:1384-90	e8.	149	
7.	 Tesi	B,	Priftakis	P,	Lindgren	F,	Chiang	SC,	Kartalis	N,	Lofstedt	A,	et	al.	Successful	150	
Hematopoietic	Stem	Cell	Transplantation	in	a	Patient	with	LPS-Responsive	Beige-Like	Anchor	151	
(LRBA)	Gene	Mutation.	J	Clin	Immunol	2016;	36:480-9.	152	
8.	 Sari	S,	Dogu	F,	Hwa	V,	Haskologlu	S,	Dauber	A,	Rosenfeld	R,	et	al.	A	Successful	HSCT	in	153	
a	Girl	with	Novel	LRBA	Mutation	with	Refractory	Celiac	Disease.	J	Clin	Immunol	2016;	36:8-154	
11.	155	
9.	 Bakhtiar	S,	Gamez-Diaz	L,	Jarisch	A,	Soerensen	J,	Grimbacher	B,	Belohradsky	B,	et	al.	156	
Treatment	of	Infantile	Inflammatory	Bowel	Disease	and	Autoimmunity	by	Allogeneic	Stem	157	
Cell	Transplantation	in	LPS-Responsive	Beige-Like	Anchor	Deficiency.	Front	Immunol	2017;	158	
8:52.	159	
	160	
	 	161	
	 8	
Legends	162	
	163	
Table	1.	Clinical	characteristics	and	laboratory	parameters	of	12	LRBA-deficient	patients	164	
who	underwent	allogeneic	hematopoietic	stem	cell	transplantation	(HSCT).	Abbreviations:	165	
(+3yrs)	or	(d+84)	,time	point	after	HSCT;	ADEM,	acute	disseminated	encephalomyelitis;	AdV,	166	
adenovirus;	aGvHD,	acute	graft-versus-host	disease;	AIHA,	autoimmune	hemolytic	anemia;	167	
AZT,	azathioprine;	cGvHD,	chronic	graft-versus-host	disease;	CMV,	cytomegalovirus;	CNS,	168	
central	nervous	system;	CR,	complete	remission;	CSA,	cyclosporine	A;	CVID,	common	169	
variable	immunodeficiency;	FK,	tacrolimus/FK506;	FU,	follow-up;	GCSF,	granulocyte	colony	170	
stimulating	factor;	GPR,	good	partial	remission	(mild	residual	symptoms-	potentially	LRBA-171	
related-	but	without	requirement	of	immunosuppressive	treatment);	het,	heterozygous;	172	
IDDM,	insulin-dependent	diabetes	mellitus	–in	this	case	as	sequelae	after	pancreatitis;	IS,	173	
immunosuppressive	drugs;	IVIG,	regular	intravenous	immunoglobulin	replacement	174	
therapy;LRBA,	lipopolysaccharid-responsive	beige-like	anchor	protein;	MFD,	matched	family	175	
donor;	MMF,	mycophenolate	mofetil;	MMFD,	mismatched	family	donor;	MSD,	matched	176	
sibling	donor;	MTX,	metothrexate;	MUD,	matched	unrelated	donor;	n.d.	,no	data	or	not	177	
determined;	PR,	partial	remission	(moderate	residual	symptoms-	potentially	LRBA-related-	178	
with	requirement	of	immunosuppressive	treatment);	SC	boost,	stem	cell	boost;	SCIG,	regular	179	
subcutaneous	immunoglobulin	replacement	therapy;	steroids,	glucocorticoids;	T,	B,	T	and	B	180	
lymphocytes;	TMA,	thrombotic	microangiopathy;	TRA,	thrombopoietin	receptor	agonist	181	
treatment;	TRM,	transplant-related	mortality;	WBC,	white	blood	cells;	wt,	wild-type.	182	
	183	
	184	
Figure	1.	Qualitative	and	semiquantitative	assessment	of	disease	activity	of	12	patients	185	
with	LRBA	deficiency	before	and	after	hematopoietic	stem	cell	transplantation.	A,	A	heat	186	
map	of	LRBA-related	symptoms	is	shown	indicating	symptom	severity	in	patients	before	and	187	
after	HSCT	in	pairs	of	columns	(white:	absent;	light	grey,	mild-moderate;	dark	grey:	severe	188	
and	considered	as	HSCT	indication;	black	columns	indicate	deceased	patients).	B,	number	of	189	
symptoms	(as	listed	in	A)	before	and	after	HSCT.	C,	Karnovsky/Lansky	performance	scores	190	
before	and	after	HSCT;	deceased	patients	were	excluded	from	the	analysis	after	HSCT.	D,	191	
number	of	immunosuppressive	drugs	used	simultaneously	or	sequentially	for	the	treatment	192	
of	LRBA-related	symptoms	before	and	after	HSCT.	E,	immunoglobulin	therapy	shown	as	193	
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none	(bottom	line);	sporadic,	indicating	use	as	irregular	immunomodulatory	treatment	194	
(center	level);	or	regular,	indicating	monthly	intravenous	or	weekly	subcutaneous	195	
replacement	therapy	(top).		196	
	197	
	198	
Table	1.	Clinical	characteristics	and	laboratory	parameters	of	12	LRBA-deficient	patients	who	underwent	allogeneic	hematopoietic	stem	cell	
transplantation	(HSCT).	
	
Patient	
characteristics	
1	 2	 3	 4	 5	 6	 7	 8	 9	 10	 11	 12	
mutation	 c.7162delA	 c.5505delT	 c.675G>A	 c.1420G>A;	
c.2834_2837
delTCTT	
c.7162delA	
	
c.2004+2A>
G	
	
c.3647_3651
delCTAA;	
c.7937T>G	
Exon	1-30	
deletion	
	
c.2978C>G	
	
c.4522	C>T		
	
c.7937T>G	
	
c.2762G>C	
	
age	at	onset	(yrs)	 7	 1	 3	 3	 2	 3	 0,1	 4	 1	 3	 1	 4	
Previous	publication	 [7]	 [8]	 *	 [1]	 [1;	6]	 [1]	 [9]	 [1]	 *	 *	 *	 *	
LRBA-directed	treatment	before	SCT	
steroids	 X	 X	 X	 X	 X	 X	 X	 X	 X	 X	 X	 X	
rituximab	 	 	 	 	 X	 	 X	 X	 X	 X	 	 X	
abatacept	 	 	 	 	 	 	 	 	 	 	 X	 	
sirolimus	 	 	 	 X	 X	 	 X	 	 	 X	 X	 	
hydroxychloroquine	 	 	 	 	 	 	 	 	 	 X	 X	 	
MMF	 	 	 X	 	 	 	 	 X	 X	 X	 	 	
azathioprine	 X	 	 	 	 	 X	 X	 	 	 X	 	 	
other	IS	 	 	 CSA/FK	 CSA/FK,	
Infliximab	
	 CSA/FK,	
Basilixi-
mab	
MTX,	
CSA/FK	
	 	 CSA/FK	 	 not	
specified	
IVIG	 X	 X	 X	 X	 X	 X	 X	 	 X	 X	 X	 X	
SCIG	 X	 	 X	 	 	 	 	 X	 X	 	 	 	
SCT	conditioning	&	course	
Indication	for	SCT	 severe	CVID-
related	
clinical	
problems,	
ADEM	
severe	
clinical	
course	un-
responsive	
to	treatment	
severe	
clinical	
course	un-
responsive	
to	treatment	
chronic	
interstitial	
lung	disease,	
chronic	
inflamma-
tory	bowel	
disease	
refractory	
pancyto-
penia	and	
lympho-
proliferation	
Recurrent	
respiratory	
infections	&	
insufficiency,	
pancyto-
penia,	
lympho-
proliferation	
enteropathy,	
auto-
immunity	
Steroid	
refractory	
lymphocytic	
insterstitial	
pneumonia	
severe	
clinical	
course,	
enteropathy,	
infections,	
failure	to	
thrive	
Refractory	
CNS	lympho-
proliferation	
Lympho-
proliferation	
severe	
humoral	
immuno-
deficiency,	
intestinal	
problems,	
auto-
immunity	
age	at	HSCT	(yrs)	 13	 12	 7	 11	 10	 6	 11	 10	 3	 16	 9	 10	
year	of	SCT	 2013	 2014	 2015	 2015	 2005	 2013	 2010	 2012	 2015	 2015	 2016	 2009	
donor	type		
(&	LRBA	status)	
MFD	
(het)	
MSD	
(n.d.)	
MSD	
(het)	
MUD	
(n.d.)	
MFD	
(het)	
MMFD	
(het)	
MSD	
(het)	
MUD	
(n.d.)	
MFD		
(wt)	
MUD	
(n.d.)	
MSD	
(het)	
MUD	
(n.d.)	
Table	1.	Clinical	characteristics	and	laboratory	parameters	of	12	LRBA-deficient	patients	who	underwent	allogeneic	hematopoietic	stem	cell	
transplantation	(HSCT).	
Patients	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	 11	 12	
SCT	conditioning	&	course	(continued)	
Fludarabin		&	
serotherapy	
X	 X	 X	 X	 X	 X	 X	 X	 X	 X	 X	 X	
Treosulfan	 X	 	 	 	 	 	 	 	 X	 	 X	 	
Busulfan	 	 X	 X	 	 	 	 	 	 	 X	 	 	
Thiotepa	 	 	 	 X	 	 X	 X	 	 	 	 	 	
Melphalan	 	 	 	 	 X	 X	 X	 X	 	 	 	 X	
aGvHD	 	 	 	 	 	 1°	(skin)	 1°-2°	(skin)	 	 	 	 	 	
cGvHD	 	 	 	 	 	 	 	 	 	 limited:		
eye,	gut	
	 	
peri-SCT	infections	 	 	 	 aspergillosis	
&	CMV		
(pre-SCT)	
	 AdV	 	 AdV,	CMV	 	 	 	 	
post-SCT	
complications	/	
TRM	and		
cause	of	death	
	 	 	 invasive	
aspergillosis	
post-SCT	
autoimmune	
hepatitis,	
successfully	
treated	with	
AZT	and	
resolved	
respiratory	
failure,	lung	
fibrosis,	
granuloma,	
adenovirus	
pneumonia,	
graft	
rejection	
	 TMA,	AdV	
viremia,	
pneumonitis	
Post-SCT	
AIHA	
	 still	requires	
hemato-
poietic	
growth	
factor	
support,	may	
need	SC	
boost	
poor	
engraftment,	
CMV	
pneumonitis,	
Enterobacter	
and	Acineto-
bacter	sepsis	
outcome	
overall	survival	 X	 X	 X	 	 X	 	 X	 	 X	 X	 X	 	
FU	(months)	 36	 25	 27	 (3)	 142	 (3)	 75	 (2)	 22	 9	 4	 (2)	
Donor	chimerism	
(%	WBC	unless	
otherwise	stated)	
>95	T,	B,	
myeloid	
(+3yrs)	
98		
(+2yrs)	
83	WBC,	
84	CD3+	
(+2yrs$)	
100	
(d+100)	
100	
(+3yrs)	
n.a.	 100		
(+3yrs)	
100	
(d+30)	
7	WBC,	
23	CD3+	
(d+578$)	
97	WBC,	
44	CD3+	
(d+180)	
100	
(d+120)	
0	(d+30)	
remission	status	 GPR	
(mild	
thrombocyto
penia	and	
thyroid	
disease)	
CR	 PR	
(moderate	
cITP	and	
AIHA)	
died	
3m	post-SCT	
(TRM)	
GPR	
(mild	cITP,	
vitiligo)	
died	
3m	post-SCT	
(TRM)	
CR	 died	
2m	post-SCT	
(TRM)	
PR	
(AIHA;	
irreversible	
IDDM	after	
pancreatitis)	
CR	 GPR	
(thrombocyt
openia,	
neutropenia,	
flares	of	
arthritis)	
died	
2m	post-SCT	
(TRM)	
current	treatment	 none	 none	 TRA,	
sirolimus,	
IVIG	
n.a.	 TRA	
(recently	
discont’d)	
n.a.	 none	 n.a.	 abatacept
IVIG	
none	 TRA,	
GCSF	
n.a.	
Table	1.	Clinical	characteristics	and	laboratory	parameters	of	12	LRBA-deficient	patients	who	underwent	allogeneic	hematopoietic	stem	cell	
transplantation	(HSCT).	
*	manuscripts	(single	patient	reports)	in	preparation	(personal	communication).	
$	declining	donor	chimerism	in	patient	3	from	95-99%	donor	WBC	with	91%	donor	T	cells	(days	+30,	+60)	to	89%	WBC	and	88%	CD3+	(day+240),	
and	further	decreasing	to	83%	WBC	and	84%	T	cell	chimerism	two	years	after	HSCT;	and	in	patient	9	from	100%	donor	WBC	days	+30	and	+60	to	
93%	on	day	+82,	which	further	declined	to	15%	WBC	and	31%	CD3+	on	day+430	and	down	to	7%	donor-derived	WBC	and	23%	CD3+	T	cells	day	
+578	at	the	latest	follow-up	(as	shown).		
AI-cytopenia
hypogammaglobulinemia
lymphoproliferation | organomegaly
enteropathy | IBD
severe infections
parenchymal lung disease | LIP | GLILD
arthritis
skin or eye manifestations
endocrinopathy | IDDM
AI-hepatitis
nephropathy | tubulopathy
neurologic manifestations
failure to thrive
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